Stephen Rusckowski

Ladies and gentlemen, let me welcome you to this annual general meeting of QIAGEN. My name is Stephen Rusckowski, I serve as the Chairman of the Supervisory Board. I'm joined today by my colleagues from the Supervisory Board, Bert van Meurs, Eva van Pelt, Eva Pisa, Mark Stevenson and Elizabeth Tallett. We're also joined by 2 Managing Board members, Thierry Bernard and Roland Sackers. We're also joined today by Casper Nagtegaal to my right. He's a partner for De Brauw Blackstone Westbroek, and Mr. [indiscernible] from our auditors, E&Y.

Before we begin the agenda, let me take a moment to go through a few procedural details. First, this meeting is being webcast live on the Internet, and the audience is in listen-only mode. Second, in accordance with past practice, all shareholders present or represented at the beginning of this meeting will be deemed to be here for the entire meeting. The official language shall be English. Mr. Nagtegaal will formally -- has been formally appointed as the Secretary. If we have any questions in Dutch, he will translate them along with our answers. The record date for shareholders and entitled to vote by proxy was May 27, 2026. On that date, the total number of shares with voting rights accounted to 206,250,011. Mr. Nagtegaal, would you please hand me the attendance list, let me count the votes present and represented at this meeting. Thank you.

According to the attendance list, I can inform you that the holders of 165,431,591 common shares in the capital of QIAGEN are